ArticleWorld journal of gastroenterology2024
Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway.
Article in World journal of gastroenterology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Probiotic Modulation of Gut Microbiota: Antioxidant Mechanisms and Clinical Benefits in Obesity and Type 2 Diabetes Management.Antioxidants (Basel, Switzerland) · 2026Review
- Therapeutic Potential ofFood science & nutrition · 2025Article
- Nutrients as epigenetic modulators in metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Review
- Herbal medicine as a potential treatment for non-alcoholic fatty liver disease.World journal of gastroenterology · 2025Article
- Fanlian Huazhuo formula: A promising therapeutic approach for metabolic associated steatotic liver disease.World journal of gastroenterology · 2025Article
- Fanlian Huazhuo Formula: A promising herbal preparation for metabolic liver disease.World journal of gastroenterology · 2024Review
- Potential of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease: A promising future.World journal of gastroenterology · 2024Article
- Gut microbiota in gastrointestinal diseases: Insights and therapeutic strategies.World journal of gastroenterology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFanlian Huazhuo Formula (FLHZF) has the functions of invigorating spleen and resolving phlegm, clearing heat and purging turbidity. It has been identified to have therapeutic effects on type 2 diabetes mellitus (T2DM) in clinical application. Non-alcoholic fatty liver disease (NAFLD) is frequently diagnosed in patients with T2DM. However, the therapeutic potential of FLHZF on NAFLD and the underlying mechanisms need further investigation.
aimTo elucidate the effects of FLHZF on NAFLD and explore the underlying hepatoprotective mechanisms
methodsHepG2 cells were treated with free fatty acid for 24 hours to induce lipid accumulation cell model. Subsequently, experiments were conducted with the different concentrations of freeze-dried powder of FLHZF for 24 hours.
resultsFLHZF had therapeutic potential against lipid accumulation and abnormal changes in biochemical indicators
conclusionFLHZF alleviates abnormal lipid metabolism in NAFLD models by regulating reactive oxygen species, autophagy, apoptosis, and lipid synthesis signaling pathways, indicating its potential for clinical application in NAFLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.